FreshPatents.com Logo


new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Glaxo Group Limited
Glaxo Group Limited A Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

Glaxo Group Limited patents


      
Recent patent applications related to Glaxo Group Limited. Glaxo Group Limited is listed as an Agent/Assignee. Note: Glaxo Group Limited may have other listings under different names/spellings. We're not affiliated with Glaxo Group Limited, we're just tracking patents.

ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Glaxo Group Limited-related inventors


Search recent Press Releases: Glaxo Group Limited-related press releases
Count Application # Date Glaxo Group Limited patents (updated weekly) - BOOKMARK this page
12015008034303/19/15Benzofuran compounds for the treatment of hepatitis c virus infections
22015008036903/19/15Novel compounds
32015006420103/05/15Antigen binding proteins to oncostatin m (osm)
42015006550703/05/15Novel compounds
52015004537502/12/15Novel compounds
62015000410501/01/15Novel composition
72014037848712/25/14Tricyclic compounds, preparation methods, and their uses
82014037126412/18/14Muscarinic acetylcholine receptor antagonists
92014033508311/13/14Methods of treatment and prevention of eye diseases
102014031197710/23/14Use of organic solvent nanofiltration and liquid-liquid chromatography for the recovery of pharmaceutical products
112014028813309/25/143 -amino- pyrazole derivatives useful against tuberculosis
122014022725908/14/14Modified proteins and peptides
132014022726408/14/14Drug fusions and conjugates with extended half life
142014020560407/24/14Antigen binding constructs
152014020566107/24/14Formulation for retinoid-containing soft gelatin capsules
162014020021807/17/14Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
172014019340707/10/14Drug fusions and conjugates
182014018775007/03/14Methods for selecting protease resistant polypeptides
192014017971506/26/142,3-dihydroimidazo[1 ,2-c] pyrimidin-5(1 h)-one compounds use as lp-pla2 inhibitors
202014015870406/12/14Medicament dispenser
212014014099605/22/14Anti-serum albumin biding variable domains
222014011643405/01/14Dry powder inhaler compositions
232014011292904/24/14Tumour necrosis factor receptor 1 antagonists
242014011388804/24/14Novel combination of therapeutic agents
252014011392204/24/14Compounds
262014010589404/17/14Humanized anti-il-18 antibodies
272014010591504/17/14Bcma (cd269/tnfrsf17) - binding proteins
282014007631403/20/14Manifold for use in medicament dispenser
292014008086303/20/14Muscarinic acetylcholine receptor antagonists
302014005690002/27/14Method for inhibiting binding to b-cell receptor
312014005810502/27/14Substituted diketopiperazines and their use as oxytocin antagonists
322014005071902/20/14Antibodies
332014005172002/20/14N-cyclobutyl - imidazopyridine - methylamine as trpv1 antagonists
342014003898902/06/14Tetrahydropyrazolo [1,5-a] pyrimidine as anti-tuberculosis compounds
352014002359601/23/14Novel composition
362014002455801/23/14Method of treatment
372014000517701/02/14Pyridinyl- and pyrazinyl-methyloxy-aryl derivatives useful as inhibitors of spleen tyrosine kinase (syk)
382014000518801/02/14Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
392013034546512/26/13Process for the preparation of retigabine
402013033698912/19/13Methods of identifying a patient population
412013031590111/28/13Novel uses
422013031704111/28/13Compounds
432013031028111/21/13Novel antigen binding proteins
442013030233511/14/13Ligands that bind tgf-beta receptor ii
452013026771710/10/13Process for the preparation of atovaquone
462013026118510/03/13Benzamide derivatives as ep4 receptor agonists
472013025172409/26/13Antigen binding proteins to oncostatin m (osm)
482013025318809/26/13Novel compounds
492013023750109/12/13Benzofuran compounds for the treatment of hepatitis c virus infections
502013022420408/29/13Method of treatment based on atad2 inhibitors
512013021315408/22/13Method of determining cleanliness
522013021339408/22/13Dispensing device
532013021765808/22/13Pyrazole compounds acting against allergic, inflammatory and immune disorders
542013021089208/15/13Method of treatment
552013020370508/08/13Pyrazole compounds acting against allergic, immune and inflammatory conditions
562013020380208/08/133 -amino- pyrazole derivatives useful against tuberculosis
572013019641208/01/13Magi polynucleotides, polypetides, and antibodies
582013018925507/25/13Fusions and conjugates of insulinotropic agents
592013013133805/23/13Substituted diketopiperazines as oxytocin antagonists
602013011813205/16/13Machine and pharmaceutical and pharmaceutical-like product assembly
612013010969005/02/13Novel crystalline forms of (3r, 6r)-3-(2,3-dihydro-1h-inden-2-yl)-1-[(1r)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1s)-1-methylpropyl]-2,5-piperazinedione
622013010278304/25/13Substituted diketopiperazines and their use as oxytocin antagonists
632013007819803/28/13Novel use
642013005337502/28/13Amino-quinolines as kinase inhibitors
652013003947002/14/13Sample plate for an x-ray powder diffraction apparatus
662013004098402/14/137-(lh-pyrazol-4-yl)-1,6-naphthyridine compounds as syk inhibitors
672013003001201/31/13Compounds
682013003001501/31/13Muscarinic acetylcholine receptor antagonists
692013002354101/24/13Voltage-gated sodium channel blockers
702013001249101/10/13Pyrimidine derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
712012031620212/13/12Compounds which have activity at m1 receptor and their uses in medicine
722012030972512/06/12Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
732012030978912/06/12Compounds which have activity at m1 receptor and their uses in medicine
742012028854411/15/12Novel retigabine composition
752012027727911/01/12Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions
762012025146810/04/12Compositions comprising alginates with high guluronic acid/mannuronic acid ratio for use in the treatment of dentine hypersensitivity
772012024074209/27/12Novel device
782012024517109/27/12Benzpyrazole derivatives as inhibitors of pi3 kinases
792012023855909/20/12Novel compounds
802012023857109/20/12Indazole derivatives as pi 3-kinase
812012023206109/13/12Novel compounds
822012020774908/16/12Dosing regimen
832012020281108/09/12Novel compounds
842012015744606/21/12Medical use
852012015749106/21/12Muscarinic acetylcholine receptor antagonists
862012015749206/21/12Antibiotic drug
872012014971106/14/12Piperidine derivatives used as orexin antagonists
882012014973106/14/12New medical use
892012012868905/24/12Anti-il-23 immunoglobulins
902012012977805/24/12Ligand that bind tgf-beta receptor rii
912012011464705/10/12Anti-serum album single variable domains
922012010013704/26/12Immunoglobulins
932012010108304/26/12S1p1 agonists comprising a bicyclic n-containing ring
942012010108604/26/12Thiadiazole derivatives and their use for the treatment of disorders mediated by s1p1 receptors
952012010112404/26/121,2,4-oxadiazol derivatives, their pharmaceutical compositions and their use as sphingosine 1-phosphate 1 receptor agonists
962012010113404/26/125-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists
972012010113604/26/125-membered heteroaryl derivatives used as sphingosine 1- phosphate receptor agonists
982012006517703/15/12Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
992012005896303/08/12Macrolides with anti-inflammatory activity
1002012004625802/23/12Novel crystalline pharmaceutical product
1012012004646902/23/12Process for the preparation of a biphenyl-2-yl carbamic acid ester
1022012003982002/16/12Antibacterial composition comprising 4-isopropyl-3-methylphenol and zinc ions
1032012004099102/16/123-azabicyclo [4.1.0] heptanes used as orexin antagonists
1042012004102702/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1052012004102802/16/12Benzimidazoles which have activity at m1 receptor and their uses in medicine
1062012003431202/09/124-isopropyl-3-methylphenol for the treatment of inflammation
1072012000632201/12/12Drug dispenser
1082012000422901/05/12Substituted diketopiperazines and their use as oxytocin antagonists
1092011031937112/29/11Pharmaceutical formulations comprising 4-hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
1102011030569212/15/11Antigen-binding contructs
1112011030569312/15/11Anitigen-binding constructs
1122011028809811/24/11Novel compounds
1132011028190911/17/11Substituted quinoline derivatives as h1 receptor antagonists
1142011027565511/10/11Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
1152011027566111/10/11Tricyclic nitrogen compounds used as antibacterials
1162011026973811/03/11Compounds
1172011026997011/03/11Phenethanolamine derivatives for treatment of respiratory diseases
1182011026358810/27/11Tricyclic compounds as glutamate receptor modulators
1192011025375210/20/11Nozzle for a nasal inhaler
1202011025607410/20/11Novel use
1212011024547010/06/11Immunoglobulins
1222011023779209/29/11Quinoline derivatives and their use as 5-ht6 ligands
1232011019027408/04/11Salt of, and processes for the preparation of, 1-isopropyl-4-hexahydro-1h-1,4-diazepine
1242011017806307/21/11Benzpyrazol derivatives as inhibitors of pi3 kinases
1252011016615007/07/11Anhydrous crystal form of ovrepitant maleate
1262011015087106/23/11Treatment of an autoimmune disease using il-18 antagonists
1272011015226206/23/11Novel compounds
1282011014282406/16/11Antibodies against amyloid-beta peptide
1292011014415106/16/11Novel process, salts, composition and use
1302011013569506/09/11Oral dosage form for controlled drug release
1312011013042306/02/11Compounds which have activity at m1 receptor and their uses in medicine
1322011011719005/19/11Pharmaceutical formulations
1332011011826105/19/11Bis-pyridylpyridones as melanin-concentrating hormone receptor 1 antagonists
1342011006164603/17/11Drug dispenser
1352011006474003/17/11Antigen binding proteins
1362011006572503/17/11Triazole amide derivatives for use in therapy
1372011005916703/10/11Encapsulation of biologically active agents
1382011005997903/10/11Piperidine/cyclohexane carboxamide derivatives for use as vanilloid receptor modulators
1392011004502702/24/11Adjuvant
1402011004613702/24/11Pyrazole derivatives as p2x7 modulators
1412011003452402/10/11Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor
1422011002157801/27/11Compounds which potentiate the ampa receptor and uses thereof in medicine
1432011000939401/13/11Tricyclic nitrogen compounds and their use as antibacterial agents
1442011000963101/13/11Phenethanolamine derivatives for treatment of respiratory diseases
1452010032999612/30/10Novel combination of therapeutic agents
1462010032402212/23/10Novel compounds
1472010031657912/16/10Novel use of alkyl phosphate esters
1482010031766612/16/10Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss
1492010031767212/16/10Monomaleate monohydrate salt of a 5ht1a receptor antagonist
1502010030808212/09/10Dispensing device
1512010031170612/09/10Method of treatment of allergic rhinitis
1522010031173412/09/10Spiro compounds useful as antagonists of the h1 receptor
1532010030382112/02/10Immunoglobulins
1542010030510712/02/10Quinoline derivatives and their use as 5-ht6 ligands
1552010030512712/02/10Novel compounds
1562010030516612/02/10Novel compounds
1572010029222411/18/10Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators
1582010029229511/18/105-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators
1592010028615211/11/10N-phenyl hydrazides as modulators of the ghrelin receptor
1602010027590911/04/10Actuator for an inhaler
1612010027385310/28/10Novel isoindol derivatives as ep4 receptor agonists
1622010026769110/21/10Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
1632010026773410/21/10N-[(3,5-dichlorophenyl)methyl]-2-(4-methyl-1-piperazinyl)-2-(1-naphthalenyl)ethanamide as ghrelin receptor modulator
1642010025619910/07/10Crystalline form of an antimalarial compound
1652010025691910/07/10Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
1662010023966609/23/10Process for producing mouldings from (meth) acrylate copolymers by means of injection moulding
1672010022418509/09/10Actuator for an inhaler
1682010022234909/02/10Quinoline derivatives used to treat inflammatory and allergic diseases
1692010021679908/26/10Phthalazine and pyrido[3,4-d]pyridazine compounds as h1 receptor antagonists
1702010021683708/26/10Glycine transport inhibitors
1712010021067208/19/10Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
1722010020325608/12/10Method and the application of powder material to substrates
1732010020424208/12/10Piperazine derivative having affinity for the histamine h3 receptor
1742010020427308/12/10Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
1752010019767908/05/10Compounds
1762010019769908/05/10I-oxa-3-azaspiro (4.5) decan-2-one and 1-oxa-3, 8-diazaspiro (4.5) decan-2-one derivatives for the treatment of eating disorders
1772010019076407/29/10Novel compounds
1782010018477007/22/10Compounds
1792010018499607/22/10Process of amide formation
1802010017569807/15/10Capsule
1812010017406507/08/10Compounds
1822010014809106/17/10Method and system for rapid phase luminescense spectroscopy analysis
1832010015219506/17/10Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
1842010014401606/10/10Apparatus for the disruption of animal cells
1852010014475506/10/10Novel compounds
1862010014482906/10/10Novel receptor antagonists and their methods of use
1872010014504006/10/10Benzazepine derivatives for the treatment of neurological disorders
1882010013727606/03/10Compounds which potentiate ampa receptor and uses thereof in medicine
1892010013735306/03/10Tricyclic compounds as antibacterials
1902010013737806/03/10Pyridine compounds for the treatment of prostaglandin mediated diseases
1912010013742806/03/10Oxygen containing heterocycles as glycine transporter inhibiting compounds
1922010013058305/27/10Prolinamide derivatives as modulators of voltage-gated sodium channels
1932010011352105/06/10Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2s-phenylpiperidin-3s-yl-)
1942010011352805/06/10Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
1952010011379605/06/10Indole derivatives as s1p1 receptor
1962010010565204/29/10Purines as cysteine protease inhibitors
1972010010568804/29/10Pharmaceutical compositions comprising 3,5-diamino-6-(2,3-dichlophenyl)-1,2,4-triazine or r(-)-2,4-diamino-5-(2,3-dichlorophenyl)-6-fluoromethyl pyrimidine and an nk1
1982010010575404/29/105-(4phenyl)prolinamide for treatment of epilepsy
1992010008742404/08/10Tricyclic nitrogen containing heterocycles as antibacterial agents
2002010008750204/08/10Indazoles used to treat estrogen receptor beta mediated disorders
2012010008766704/08/10Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
2022010008183004/01/10Methods of synthesizing n-hydroxysuccinimidyl carbonates
2032010007595303/25/10Substituted piperazines, (1,4) diazepines, and 2,5-diazabicyclo (2.2.1) heptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists
2042010007598203/25/10Pyridinone derivative for the treatment of premature ejaculation
2052010006816603/18/10Oral composition comprising dimethicone copolyol
2062010006940903/18/10"novel compounds"
2072010006941603/18/10Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine d3 receptors
2082010005905203/11/10Sheet driver for use in a drug dispenser
2092010006309703/11/10Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine d3 receptors
2102010005650203/04/10Compounds
2112010005652703/04/10Benzofuran compounds useful in the treatment of conditions mediated by the action of pge2 at the ep1 receptor
2122010005659503/04/10Pyrazole derivatives as p2x7 modulators
2132010004863902/25/10Oxadiazole derivates as s1p1 receptor agonists
2142010004167202/18/10Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome
2152010002969902/04/10Matrix metalloproteinase inhibitors
2162010001628701/21/10Compounds having affinity for dopamine d3 receptor and uses thereof"
2172010001637101/21/10Indole compounds
2182010001002101/14/10Novel compounds
2192010000052801/07/10Manifold for use in medicament dispenser
2202010000052901/07/10Manifold for use in medicament dispenser
2212010000342001/07/10Medicament dispenser
2222010000423001/07/10Azatricyclic compounds and their use
2232010000424001/07/10Indole compounds
2242009032595212/31/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2252009032603212/31/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2262009031849412/24/09Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
2272009031852312/24/09Benzoisoindole derivatives and their use as ep4 receptor agonists
2282009031853012/24/09Pharmaceutical compositions comprising nk1 receptor antagonists and sodium channel blockers
2292009031238812/17/09Benzo [f] isoindoles as ep4 receptor agonists
2302009031254612/17/09Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
2312009030605212/10/09Indenyl derivatives and use thereof for the treatment of neurological disorders
2322009029874212/03/09Process for manufacturing lactose
2332009029114611/26/09Process for manufacturing lactose
2342009029198711/26/09Novel polymorph of (5-amino-6-methoxy-3-pyridincarbonyl) carbamic acid 2-(s)-hydroxymutilin 14-ester
2352009028676211/19/09Pharmaceutical formulations comprising azelastine and a corticosteroid for the treatment of inflammatory or allergic conditions
2362009027560411/05/09M3 muscarinic acetylcholine receptor antagonists
2372009027035510/29/09Compounds
2382009027051010/29/09Glycine transport inhibitors
2392009025390810/08/09Novel m3 muscarinic acetylchoine receptor antagonists
2402009023644509/24/09Fluid dispenser
2412009023984609/24/09Novel compounds
2422009023284709/17/09Immunogenic compositions
2432009022754709/10/09Novel salt form of a beta2-adrenergic agonist quinolin-2-one derivative
2442009022762909/10/09Compounds having activity at the glycine transporter glyt1 and uses thereof
2452009022157709/03/09Compounds having morpholinyl and piperidinyl groups for use as glyt1 inhibitors
2462009021120108/27/09Apparatus and printing packaging elements
2472009020947208/20/09Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents
2482009020365708/13/09Dual pharmacophores - pde4-muscarinic antagonistics
2492009020367708/13/09Dual pharmacophores - pde4-muscarinic antagonistics



ARCHIVE: New 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Glaxo Group Limited in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Glaxo Group Limited with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###

     SHARE